RedHill Biopharma Ltd (RDHL)

[noretreat]

Add on the dips! Summary

Talicia (RHB-105) is a Phase 3 triple combination therapy drug candidate in clinical trial for eradication of H. pylori infection. Top-line data readout for Talicia is expected late Q4/2018.

The pathophysiological effects of H. pylori in the gastrointestinal tract are broad including gastric cancer, the most lethal cancer in the world, that accounts for >750,000 death annually.

In US, 117M individuals are infected with H. pylori, a serious chronic transmissible infectious agent, with global prevalence estimated at 4.32 billion.

RedHill proposes Talicia as an innovative, advanced first-line therapy for eradication of H. pylori irrespective of ulcer status. I also clarify why placebo was used in the first Talicia trial.

Is this doable? I say 'yes' and offer my thorough analysis based in part on my call interview with Gilead Raday, COO at RedHill Biopharma.

https://seekingalpha.com/article/4220502-redhill-talicia-say-yes?app=1